Literature DB >> 7841034

Temperature sensitivity for conformation is an intrinsic property of wild-type p53.

P Hainaut1, S Butcher, J Milner.   

Abstract

The tumour-suppressor protein p53 is a metal-binding transcription factor with sequence-specific DNA-binding capacity. In cancer, mutation of p53 disrupts protein conformation with consequent loss of DNA binding and associated tumour-suppressor function. In vitro, the conformation and DNA-binding activity of wild-type p53 are subject to redox modulation and are abrogated by exposure to metal chelators. In the present study, we have used the chelator 1, 10-phenanthroline (OP) to probe the effect of temperature on the conformational stability of p53 translated in vitro. Whereas low temperature (30 degrees C) stabilised wild-type p53 conformation and protected against chelation, high temperature (41 degrees C) promoted destabilisation and enhanced chelation, indicating that temperature influences the folding of wild-type p53. Destabilisation of p53 tertiary structure induced protein aggregation through hydrophobic interactions, consistent with the notion that wild-type p53 contains a hydrophobic core which may become exposed by metal chelation. These results indicate that temperature sensitivity for conformation is an intrinsic property of wild-type p53 and suggests that small changes in temperature may directly affect p53 function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7841034      PMCID: PMC2033583          DOI: 10.1038/bjc.1995.48

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.

Authors:  J Milner; E A Medcalf; A C Cook
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

2.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

Authors:  D Michalovitz; O Halevy; M Oren
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

3.  Molecular basis for heterogeneity of the human p53 protein.

Authors:  N Harris; E Brill; O Shohat; M Prokocimer; D Wolf; N Arai; V Rotter
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

4.  Evidence that immunological variants of p53 represent alternative protein conformations.

Authors:  J Gamble; J Milner
Journal:  Virology       Date:  1988-02       Impact factor: 3.616

5.  Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135.

Authors:  J Milner; E A Medcalf
Journal:  J Mol Biol       Date:  1990-12-05       Impact factor: 5.469

6.  Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein.

Authors:  J Milner; J V Watson
Journal:  Oncogene       Date:  1990-11       Impact factor: 9.867

7.  Evidence for allosteric variants of wild-type p53, a tumour suppressor protein.

Authors:  A Cook; J Milner
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

8.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

9.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  Precise epitope mapping of the murine transformation-associated protein, p53.

Authors:  A Wade-Evans; J R Jenkins
Journal:  EMBO J       Date:  1985-03       Impact factor: 11.598

View more
  9 in total

1.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

2.  Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

Authors:  M V Blagosklonny; J Toretsky; S Bohen; L Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 3.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

4.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

5.  Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant.

Authors:  Khaled Barakat; Bilkiss B Issack; Maria Stepanova; Jack Tuszynski
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

6.  Understanding p53 functions through p53 antibodies.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  J Mol Cell Biol       Date:  2019-04-01       Impact factor: 6.216

7.  Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast.

Authors:  Ashley S Denney; Andrew D Weems; Michael A McMurray
Journal:  G3 (Bethesda)       Date:  2021-09-06       Impact factor: 3.154

8.  The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis.

Authors:  Antoine G van der Heijden; Christina A Hulsbergen-Van de Kaa; J Alfred Witjes
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

9.  Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains.

Authors:  Kiyoto Kamagata; Saori Kanbayashi; Masaya Honda; Yuji Itoh; Hiroto Takahashi; Tomoshi Kameda; Fumi Nagatsugi; Satoshi Takahashi
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.